Secrecy and medicines

International Journal of Risk and Safety in Medicine

Volumn 9, Issue 3, 1996, Pages 133-141

  Medawar, Charles ^a  

^a Social Audit Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INFORMATION; DRUG LEGISLATION; DRUG USE; HUMAN; MEDICOLEGAL ASPECT; UNITED KINGDOM;

EID: 0030437104     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: 10.3233/jrs-1996-9302     Document Type: Article

References (19)

1. Anon, Pharmaceuticals - A Consumer Prescription and Secrecy and Medicines in Europe, National Consumer Council, London, 1991, 1994.
2. Anon, Prescription for waste, Health Which?, Consumers Association, London, February, 1996.
3. Anon, Secret Side Effects, Health Which?, Consumers Association, London, August, 1996.
4. W.A. Asscher, Strategy of risk-benefit analysis, in: Iatrogenic Diseases, P.F. D'Arcy and J.P. Griffin, eds, 3rd edn, Oxford University Press, Oxford, 1986.
5. Cabinet Office, Guidance on Interpretation on the Code of Practice on Access to Government Information, 29 March, 1994; available from the Cabinet Office, 70 Whitehall, London SW1A 2AS.
6. Campaign for Freedom of Information, Testing the Open Government Code of Practice, 1994; available from CFOI, 88 Old Street, London EC1V 9AR.
7. Chancellor of the Duchy of Lancaster, Open Government (Cm 2290), HMSO, London, 1993, pp. 48-49.
8. K. Clarke, Opren (House of Commons debate), in: Hansard, HMSO, London, 27 January 1983, p. 1121.
9. Committee on Safety of Medicines and Medicines Control Agency, Guidelines on interpretation of drug analysis prints, CSM/MCA, London, 1996.
10. S.M. Core, G. Jones and S.G. Thomson, The Lancet's statistical review process: areas for improvement by authors, The Lancet, 11 July, 1992, pp. 100-102.
11. Department of Health, Code of Practice on Access to Government Information, 1994; available from Open Government Unit, Department of Health, Richmond House, 79 Whitehall, London SW1A 2NS.
12. M.N.G. Dukes, The moments of truth, in: Side Effects of Drugs Annual 1, M.N.G. Dukes, ed., Exerpta Medica, Amsterdam, 1977, pp. v-ix.
13. Maastricht Treaty on European Union, SEC(92) 2274, Final, Brussels, December, 1992.
14. C. Medawar, Power and Dependence: Social Audit on the Safety of Medicines, Social Audit Ltd., London, 1992, p. 95.
15. P.B. Medawar, Advice to a Young Scientist, Harper & Row, New York, 1979, pp. 42-43.
16. T. Sackville, Medicines Information Bill, Hansard (Standing Committee C), 24 February, 1993, p. 48.
17. Select Committee on the Parliamentary Commissioner for Information (Second Report, HC 84, Session 1995/96), Open Government, HMSO, London, 1996, pp. xliii-xlv.
18. World Health Organisation Expert Committee, New Approaches to Health Education in Primary Health Care (TRS No. 460), WHO, Geneva, 1983.
19. P. Wingate, ed., Medical Encyclopaedia, Penguin Books, Harmondsworth, Middlesex, 1985, pp. 219-222.